Project Grant R03TR004611
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$170K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
This $103,948 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to the Sloan-Kettering Institute for Cancer Research supports research aimed at elucidating the mechanisms driving T-cell dysfunction within the tumor microenvironment. The research plan includes two main components: Predoctoral research (Aim 1) to investigate how local amino acid availability limits effector function in tumor-infiltrating T-cells, including profiling the...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support research at the University of North Carolina at Chapel Hill to investigate how the tumor microenvironment impacts T cell metabolism and antitumor immunity. The $496,391 award, with a project period from December 2024 to November 2029, will fund experiments using genetic mouse models, patient tumor samples, and preclinical CAR-T cell models to determine if the enzyme acetyl-CoA...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $132,462 to the Fred Hutchinson Cancer Center in Seattle, WA to support research aimed at improving engineered T cell receptor T cell (TCR-T) therapy for solid tumors. The key objectives are to: 1) Determine why TCR-T cells form a different reservoir of stem-like progenitor cells in tumor-draining lymph nodes compared to endogenous tumor-specific T cells, and 2)...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) in the amount of $121,857 aims to systematically investigate how anti-cancer drugs modulate T cells in the tumor microenvironment. The key objectives are to: Conduct in silico screening to identify anti-cancer drugs impacting T cell effector function, activation, stemness, and proliferation (Aim I). Perform single-cell CRISPR knockout screening to determine anti-cancer drug targets...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $163,967 to President and Fellows of Harvard College (Harvard Medical School) to conduct research on defining the functional and spatial properties of tumor-specific, tumor-infiltrating CD8 T cells. The key objectives are to: Generate patient-derived xenograft (PDX) mouse models of melanoma to test the required diversity of T cell receptors (TCRs) from tumor-infiltrating T...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Biology Research federal grant program (CFDA 93.396), provides $626,534 to The Medical University of South Carolina (MUSC) over a 5-year period beginning December 1, 2024. The grant supports research to dissect the mechanisms by which transient endoplasmic reticulum (ER) stress can enhance anti-tumor T cell responses. Key research objectives include: Determining how ER stress-induced mitochondrial quality control...
This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), will support research to gain a comprehensive understanding of how adoptive T cell therapy (ACT) becomes dysfunctional within the tumor microenvironment of pancreatic cancer. The $169,344 award, running from 09/01/2024 to 08/31/2026, will leverage single-cell and spatial multi-omics analyses, computational modeling, and functional experiments to: 1) identify targetable T...
This $674,996 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Sanford Burnham Prebys Medical Discovery Institute (SBP) to determine if targeting the PSGL-1 checkpoint inhibitor can promote the development and/or maintenance of CD8+ T cells essential for anti-tumor responses to PD-1 immune checkpoint blockade (ICB) therapy. The key objectives are to evaluate if PSGL-1 blockade can generate or sustain tumor-specific...
This Project Grant award of $147,486 from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) supports research at the University of Pittsburgh to investigate the role of altered lipid metabolism in CD8 T cell exhaustion within the tumor microenvironment. The project aims to (1) evaluate the impact of abolishing citrate transport on carbon utilization and effector function of CD8 T cells in the tumor environment, and (2) determine the role of stored lipids in CD8 T cell...
This Project Grant award of $445,996 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to investigate how mitigating oxidative stress at T cell telomeres can improve the function and efficacy of adoptive cell therapies against cancer. The research, conducted by the University of Pittsburgh, has two key objectives: Determine the mechanistic role of oxidative damage at telomeres on T cell function and how protecting telomeres with an antioxidant protein can...